Comparative Pharmacology
Head-to-head clinical analysis: DARAPRIM versus NORITATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARAPRIM versus NORITATE.
DARAPRIM vs NORITATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Daraprim (pyrimethamine) is a folic acid antagonist that inhibits dihydrofolate reductase (DHFR) in susceptible protozoa, thereby interfering with folate synthesis and blocking DNA synthesis and cell replication. It is synergistic with sulfonamides, which inhibit dihydropteroate synthase in the folate pathway.
Metronidazole, after intracellular reduction, forms toxic intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis. It has anti-inflammatory and immunosuppressive properties in dermatological conditions.
50 mg orally once daily for 2 days, then 25 mg orally once daily for 4 weeks; for toxoplasmosis, a loading dose of 200 mg orally once daily for 1 day, followed by 50-75 mg orally once daily for 4-6 weeks, with folinic acid 10-25 mg daily.
Topical application of a thin layer to affected area twice daily (morning and evening).
None Documented
None Documented
Terminal elimination half-life is approximately 111 hours (range 54-148 hours) in adults. The long half-life allows weekly dosing for toxoplasmosis treatment.
Approximately 10 hours; may be prolonged in severe renal impairment.
Primarily hepatic metabolism; renal excretion accounts for approximately 30% of elimination as unchanged drug and metabolites. Fecal excretion is minimal (<5%).
Primarily renal (approximately 90% as unchanged drug) and biliary/fecal (approximately 10%).
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent